Aprea Therapeutics Stock
Aprea Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Oren Gilad
- Employees
- 8
- Market cap
- $7 M
- IPO
- 03/10/2019
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor…
Aprea Therapeutics stock: price history
1D
-5.4%
1W
-3.3%
1M
-20.0%
6M
-41.6%
YTD
-31.5%
1Y
-62.1%
2Y
-83.3%
5Y
-99.4%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Aprea Therapeutics
Analyst assessment of Aprea Therapeutics
0
STRONG BUY
4
BUY
2
HOLD
2
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 13/08/2026
Aprea Therapeutics stock metrics
P/E
-0.54
P/B
0.81
EV/EBITDA
2.76
RETURN ON EQUITY
-9.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.0%
FLOAT SHARES
11,461,024
AVG. DAILY VOLUME (30D)
219,935
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Aprea Therapeutics stock
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Oren Gilad, the company employs around 8 people.
The IPO was on 03/10/2019; the stock trades on NASDAQ under the ticker APRE.
What do analysts say about Aprea Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Aprea Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Aprea Therapeutics pay a dividend?
No, Aprea Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aprea Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aprea Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aprea Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.